非小细胞肺癌纵隔分期:告别纵隔镜检查
本文围绕可切除非小细胞肺癌(NSCLC)纵隔淋巴结分期展开,指出影像学不足需组织取材,纵隔镜曾为金标准,现EBUS-FNA成为标准治疗;引Bousema等随机非劣效试验,EBUS alone不劣于EBUS加确认性纵隔镜,支持EBUS阴性后不再行确认性纵隔镜。
要点
- 可切除NSCLC纵隔淋巴结准确分期对确定肿瘤总分期和指导后续治疗至关重要。
- 分期通常始于PET或CT,但单独影像学不足,需组织取材确认淋巴结病变。
- Bousema等随机非劣效试验结论:EBUS alone不劣于EBUS加确认性纵隔镜。
核心结论
- Bousema等随机非劣效试验结论为EBUS alone不劣于EBUS加确认性纵隔镜。
- 这些发现肯定了作者当前在EBUS阴性后不行确认性纵隔镜的做法。
研究设计与样本
- Bousema等开展随机非劣效试验,比较可切除NSCLC患者单用EBUS与EBUS加确认性纵隔镜后未预见淋巴结转移率。
主要发现
- EBUS-FNA联合辅助技术(如结内钳活检和食管超声)对诊断淋巴结转移具有高敏感性和特异性。
- EBUS-FNA还能评估N1病变并获取足够组织进行肿瘤基因组分析以帮助指导治疗。
- Bousema等结论为EBUS alone不劣于EBUS加确认性纵隔镜。
关键数值与推荐
- 欧洲胸外科医师学会指南仍推荐EBUS阴性时行确认性电视纵隔镜。
- 确认性纵隔镜是否必要存在争议,北美不常进行。
临床怎么用
- 作者当前实践为EBUS阴性后不行确认性纵隔镜,上述发现肯定了该做法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.Accurate staging of the mediastinal lymph nodes in resectable non-small-cell lung cancer (NSCLC) is critically important to determine the overall stage of the tumor and guide subsequent management. The staging process typically begins with positron emission tomography (PET) or computed tomography imaging; however, imaging alone is inadequate, and tissue acquisition is required for confirmation of nodal disease. Mediastinoscopy was long considered the gold standard for staging of mediastinal lymph nodes, but, recently, endobronchial ultrasound-guided (EBUS) fine-needle aspiration (FNA) has become the standard of care. EBUS-FNA, in combination with supplementary technologies, such as intranodal forceps biopsy and esophageal ultrasonography, has a high sensitivity and specificity for the diagnosis of nodal metastases. EBUS-FNA is also capable of assessing N1 disease and obtaining adequate tissue for tumor genomic analysis to help guide treatment. In the case of negative findings on EBUS, a confirmatory video mediastinoscopy is still recommended by the European Society of Thoracic Surgeons guidelines. However, whether confirmatory mediastinoscopy is necessary is a matter of debate, and it is not commonly performed in North America. To address this question, Bousema and colleagues performed a randomized noninferiority trial to determine rates of unforeseen nodal metastases after EBUS alone versus EBUS with confirmatory mediastinoscopy in patients with resectable NSCLC. The authors concluded that EBUS alone is noninferior to EBUS with confirmatory mediastinoscopy. These findings affirm our current practice to forgo confirmatory mediastinoscopy after negative findings on EBUS.
引用
- Dunne EG, Fick CN, Jones DR, et al. Mediastinal Staging in Non-Small-Cell Lung Cancer: Saying Goodbye to Mediastinoscopy. J Clin Oncol. 2023. PMID: 37267507. doi:10.1200/JCO.23.00867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。